NEW YORK, Feb. 10, 2021 /PRNewswire/ -- Scopus BioPharma Inc. (Nasdaq: SCPS) today announced the closing of the underwriters' over-allotment option in full, bringing total follow-on public offering proceeds to $10.35 million. Scopus is a biopharmaceutical company developing...
from PR Newswire: https://ift.tt/3aR0F1f
No comments:
Post a Comment